Previous 10 | Next 10 |
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atro...
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to ...
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the i...
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (ADOA) To submit first pre-Investigational New Drug (IND) application meeting request this...
Summary I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter. I just am not sure if I should be buying Krystal Biotech at current prices, given certain issues I discuss. Krystal Biotech ( KRYS ) has ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Alextype/Shutterstock.com We’re checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subjec...
Abeona Therapeutics press release ( NASDAQ: ABEO ): Q3 GAAP EPS of -$1.48. Cash, cash equivalents, restricted cash and short-term investments totaled $23.5 million as of September 30, 2022. For further details see: Abeona Therapeutics GAAP EPS of -$1.48
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway into 3Q 2024 NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEW...
Penny Stocks To Buy According To 5 Wall Street Analysts Are analysts the ultimate factor in deciding the best penny stocks to buy? In my opinion, they are not, and if you are using analyst ratings in your research, it’s sometimes best to take them with a grain of salt. But ar...
Summary Children suffering dystrophic epidermolysis bullosa (DEB), a serious genetic disease, are affectionately called butterfly children, depicting their fragile, recurrent blistering skin with chronic open wounds. Currently, there are three potential DEB treatments that have co...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...